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Abstract Osteoporosis (OP) increases vertebral fragility as a
result of the biomechanical effects of diminished bone struc-
ture and composition. This study has aimed to assess the ef-
fects of pulsed wave low-level laser therapy (PW LLLT) on
cancellous bone strength of an ovariectomized (OVX-d) ex-
perimental rat model and a glucocorticoid-inducedOP (GIOP)
experimental rat model. There were four OVX-d groups and
four dexamethasone-treated groups. A group of healthy rats
was used for baseline evaluations. The OVX-d rats were fur-
ther subdivided into the following groups: control rats with
OP, OVX-d rats that received alendronate, OVX-d rats treated
with PW LLLT, and OVX-d rats treated with alendronate and
PW LLLT. The remaining rats received dexamethasone and
were divided into four groups: control, alendronate-treated
rats, laser-treated rats, and laser-treated rats with concomitant
administration of alendronate. PW LLLT (890 nm, 80 Hz,
0.972 J/cm2) was performed on the spinal processes of the
T12, L1, L2, and L3 vertebras. We extracted the L1 vertebrae
and submitted them to a mechanical compression test. Biome-
chanical test findings showed positive effects of the PWLLLT
and alendronate administration on increasing bending stiff-
ness and maximum force of the osteoporotic bones compared
to the healthy group. However, laser treatment of OVA-d rats
significantly increased stress high load compared to OVA-d
control rats. PW LLLT preserved the cancellous (trabecular)
bone of vertebra against the detrimental effects of OV-induced
OP on bone strength in rats compared to control OV rats.
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Introduction
Osteoporosis (OP) increases vertebral fragility as a result of
the biomechanical effects of diminished bone structure and
composition [1, 2]. Wright et al. have reported that the com-
bination of OP and low bone mass at the femoral neck or
lumbar vertebrae affected an estimated 53.6 million older
US adults in 2010 [3]. Looker et al. analyzed data from the
National Health and Nutrition Examination Survey during
2005–2008 and showed that in the USA the prevalence of
OP at the femoral neck and lumbar vertebra was 5 and 6 %,
respectively [4]. Although the incident rates have stabilized,
OP fractures, in particular the hip and vertebra, are associated
with considerable expense and increased risk of disability and
mortality [5]. Mortality is usually highest during the first year
after fracture; however, a notably increased mortality risk
might persist for several years after the event. In addition to
its efficacy in the prevention of new and recurrent osteoporotic
fractures, medical treatment has been associated with im-
proved survival after osteoporotic fractures. In their review
article through observational and randomized clinical trials,
Sattui and Saag have stated that clinical administration of
bisphosphonates not only is effective in the prevention of
OP but also increases the survival rates in patients with OP
fractures. The rationale behind this administration however
remains unclear and necessitates additional research [5].
Various animal models have been used to investigate the
pathogenesis of OP as well as facilitate preclinical testing and
new treatment options such as anti-resorptive drugs [6].
Histomorphometric parameters and biochemical markers of
bone metabolism in animal studies only indicate a decrease
in bone formation and minimal changes in bone resorption.
These parameters are less important with regards to OP-
associated fractures and investigations in orthopedic surgery.
Furthermore, histological and biochemical studies do not give
direct information about the mechanical strength of the bone.
The ultimate reason for fracture of a bone following minimal
trauma is the reduction of mechanical strength [7]. Although
bone densitometry is frequently used to assess bone fragility,
direct biomechanical testing of the bone undoubtedly provides
more information about mechanical integrity [8].
Prevention of osteoporotic vertebral fractures can assist
millions of at-risk individuals to maintain pain-free indepen-
dence and long-term health. Current treatments for OP com-
prise systemic therapies that aim to increase bone mineral
density (BMD) and reduce fracture risk [9]. Bone quality en-
compasses a number of bone tissue properties that govern
mechanical resistance such as bone geometry, cortical proper-
ties, trabecular microarchitecture, bone tissue mineralization,
quality of collagen and bone apatite crystal, and presence of
microcracks. These properties all depend on bone turnover
and its variations. Decreases in bone resorption markers
achieved with resorption inhibitors may partially predict a
decrease in fracture risk. At the spine, however, this correla-
tion exists to the level of a 40 % fall in bone resorption
markers; in a study, larger declines have not been shown to
provide additional protection against fractures in patients who
take risedronate. OP medications can exert favorable effects
on bone size and cortical thickness. Such effects have been
documented with teriparatide (PTH 1–34), which is a unique,
purely anabolic treatment for OP. More surprising are the fa-
vorable effects on bone size seen with some of the bone re-
sorption inhibitors such as neridronate in adults with osteo-
genesis imperfecta. Similarly, estrogens and alendronate can
increase femoral neck size in postmenopausal women. Pres-
ervation of the trabecular microarchitecture has been initially
demonstrated with risedronate and subsequently with
alendronate [10]. Despite the availability of efficacious treat-
ments for fracture reduction in patients with OP, there are still
unmet needs that require a broader range of therapeutics [11].
Several researchers have determined that continuous wave
(CW) low-level laser therapy (LLLT) stimulates in vitro min-
eralization through increased IGF-I and BMP production,
Runx2 expression, and ERK phosphorylation [12]. CWLLLT
has been shown to stimulate bone nodule formation [13] in
osteoblasts. Others reported that LLLT promoted the acceler-
ation of bone strength and consolidation after a fracture, cre-
ated new blood vessels, increased collagen fiber deposition,
and promoted greater bone cell proliferation at the fracture site
[14, 15]. Pinheiro et al. reported that LLLT resulted in in-
creased mineralized bone tissue in fractured femora [16].
Bossini et al. concluded that LLLT improved bone repair in
the tibia of osteoporotic rats by stimulation of newly formed
bone, fibrovascularization, and angiogenesis [17].
Ko et al. evaluated LLLT in treatment of trabecular bone
loss induced by skeletal unloading. In that study, mice
underwent denervation surgery. After denervation, CW LLLT
(wavelength, 660 nm; energy, 3 J) was applied to the tibiae of
mice. Ko et al. reported that LLLTmight enhance bone quality
and bone homeostasis associated with enhancement of bone
formation and suppression of bone resorption [18]. In another
study, Ko et al. tested the effect of LLLT in prevention and/or
treatment of osteoporotic trabecular bone. The tibiae of
ovariectomized-induced OP (OVX-d) mice were treated with
pulsed wave LLLT (PW LLLT) (660 nm, 3 J). Their results
indicated that LLLT might be effective for the prevention and/
or treatment of trabecular bone loss. This effect might be site-
dependent in the same bone [19]. Diniz et al. studied the
influence of CW LLLT in combination with bisphosphonate
on OVX-d in cancellous (trabecular) bone of the femoral neck
and vertebrae (T13–L2) of rats [20]. Their study divided 35
female rats into five groups: (1) sham-operated rats (control),
(2) OVX-d rats with OP, (3) laser-treated OVX-d rats with OP,
(4) OVX-d rats with OP treated with alendronate, and (5)
OVX-d rats with OP treated with alendronate and laser.
Groups 3 and 5 received daily oral alendronate. CW LLLT
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(830 nm, 50 mW, and 4 J/cm2) was administered to the fem-
oral neck and spinal vertebra in groups 4 and 5. Rats from the
OP control and OP + laser groups showed marked OP. In the
OP + bisphosphonate group, there was significantly more
cancellous bone volume in the vertebra than in the OP control
group. Notably, in the association between laser and
alendronate, the cancellous bone volume was significantly
greater in the vertebrae. This finding was similar to the
sham-operated control group. Diniz et al. concluded that laser
therapy associated with alendronate treatment was the best
method for reversing vertebral OP caused by an ovariectomy
[20].
Evidence exists that pulsed light dose has effects that differ
from CW [21]. The use of pulsed light is increasing and a
review of literature has shown three cellular studies on rat
calvarial cells [22–24], one in vivo study on the tooth move-
ment speed of rat molars [25], one study on bone turnover in
OVX-d rats [26], and one study on healing of partial tibial
osteotomy in streptozotocin-induced diabetic rats [27].
The aim of this study was to assess the effects of PWLLLT
on cancellous bone strength of an OVX-d experimental rat
model and a glucocorticoid-induced OP (GIOP) experimental
rat model. We evaluated bone strength by measuring the bio-
mechanical properties of the first lumbar vertebral body which
included bending stiffness (Young modulus of elasticity),
maximum force, and stress high load.
Materials and methods
Experimental animals
A total of 54 adult male and female Wistar rats, aged
4.5 months, were housed in standard rat cages in a 12-h
light/dark environment. Rats received water ad libitum. All
experimental procedures were approved by theMedical Ethics
Committee of Shahid Beheshti University of Medical Sci-
ences, Tehran, Iran (protocol no 1391-1-115-1092). The rats’
body weights were monitored weekly, and the volume of
drugs administered was calculated according to the most
recent body weights.
Study design
OVX-d rats and GIOP rats received PW LLLT and
alendronate, after which they were subjected to a mechanical
compression test.
Ovariectomized-induced osteoporosis (OVX-d) and GIOP
rats
We randomly assigned the 54 rats into nine groups of six rats
each as follows: four OVX-d groups, four groups that received
dexamethasone, and one healthy group that was considered
for baseline studies (H, group 5). Ovariectomies were per-
formed via two paravertebral skin incisions made when the
rats were anesthetized with ketamine (50 mg/kg, i.m.) and
diazepam (5 mg/kg, i.m.) [28, 29]. The uterine tubes were
ligated (catgut 4.0) and, following removal of the ovaries,
the incisions were closed (nylon 3.0). Antibiotic therapy with
ceftriaxone (Jaber ben Hayan, Tehran, Iran) at a dose of
50 mg/kg was administrated immediately before surgery and
at 24 and 48 h after surgery. All animals were kept for
14 weeks after surgery in cages in order to develop OP
[28, 29]. At the end of this period, rats were submitted to the
following treatments: group 1, control rats with OP (OC);
group 2, OVX-d rats treated subcutaneously [28] with 1 mg/kg
alendronate [30] (Alborz Darou, Tehran, Iran) for 30 days
(OA); group 3, OVX-d rats treated with PW LLLT (OL);
and group 4, OVX-d rats treated with PW LLLT and concom-
itant administration of alendronate (OAL).
In the current study, the surface area of the target tissue was
larger than the pen’s spot size; therefore, we used sequential
treatments to ensure that each unit area received a similar laser
dose [31]. PW LLLTwas performed on the spinal processes of
T12, L1, L2, and L3 vertebrae with the laser pen held perpen-
dicular to the target tissue at a distance of <1 cm. During PW
LLLT, animals were sedated by administration of 1/2 the dos-
age of the anesthesia drugs. PW LLLT was administered for
3 days per week for an 8-week period. The specifications of
the laser used are shown in Table 1 [29, 32].
The remaining rats received intramuscular injections of
dexamethasone (Alborz Darou, Tehran, Iran) at 1 mg/kg/day
administered 6 days/week for a 5-week period as a modified
protocol [33]; the referred drug administration was modified
to 6 days per week instead of 7 days per week and 5 weeks
instead of 4 weeks. After 5 weeks, we divided the rats into
four groups: group 6, control OP rats treated with intramuscu-
lar injections of vehicle (distilled water: DC); group 7, GIOP
rats treated with subcutaneous injections of 1 mg/kg
alendronate (Alborz Darou, Tehran, Iran; DA); group 8, GIOP
Table 1 Specifications of the infrared laser used
Parameters Dose and unit
Peak power output 75 W
Average power 1.08 mW
Power density 1.08 mW/cm2
Wavelength 890 nm
Pulse frequency 80 Hz
Spot size 1 cm2
Pulsed duration 180 μs
Duration of exposure for each point 900 s
Energy density 0.972 J/cm2
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rats treated with PW LLLT (DL); and group 9, GIOP rats
treated with PW LLLT and concomitant administration of
alendronate (DAL).
General examinations
At 8 weeks after the beginning of laser treatment and
alendronate administration, the rats were killed with an over-
dose of anesthesia. Blood glucose concentrations were mea-
sured using distal tail vein blood samples (GM 300, Biomince,
GMH, Heerbrugg, Switzerland). We extracted the laser-
treated vertebrae (T12–L3). The height of the first lumbar
vertebra (mm) was measured using a sliding caliper and its
weight (g) measured. T12, L2, and L3 vertebrae were frozen
for future analyses.
Biomechanical examinations
Biomechanical properties of the first lumbar vertebral body
bone were determined by the uniaxial compression test which
was performed using a material testing machine (Z 2.5, Zwick
Gm Bh & Co., Ulm-Einsingen, Germany). The rate of the
compression test was 5 mm/min, and we obtained the load–
deformation curve. In order to evaluate biomechanical behav-
ior, we measured bending stiffness (Young modulus of elas-
ticity; N/mm), maximum force (N), and stress high load
(N/mm2).
Bending stiffness is the slope of the linear portion of the
load–deformation curve (the ratio of loading to deformation in
the elastic region of the curve). Maximum force or ultimate
compression strength is the maximum load that is borne by the
first vertebral body bone. The stress high load was calculated
by dividing the maximum force by the bone’s surface area
(mm2).
Statistical analysis
All data were expressed as mean± standard errors of mean
(SEM).
Normal distribution of data was analyzed by the one-
sample Kolmogorov-Smirnov test. Parametric and nonpara-
metric statistical methods were used. The analysis of variance
(ANOVA) test was used to compare changes among groups
with normal distribution of data and the least significant dif-
ference (LSD) test to identify differences. A p value of ≤0.05
was considered statically significant. Nonparametric methods
were used for statistical analysis of other groups. These data
were analyzed using the Kruskal-Wallis andMann-WhitneyU
tests. Differences were regarded as significant if p<0.005 for
analyses between groups 1 and 9. The differences were also
regarded as significant if p≤0.01 for analyses between groups
1 and 5 and between groups 5 and 9.
Results
General observations
Blood glucose levels
According to the ANOVA test, there were no significant dif-
ferences in blood glucose levels between the studied groups
(Table 2).
Body weight
The Student’s t test showed that administration of dexameth-
asone led to a significant decrease in body weight (p<0.001).
Although we observed weight loss in all groups that received
dexamethasone, the weight loss was more severe in rats from
groups DC and DL.
In all these groups, five rats died during dexamethasone
administration and three died during alendronate treatment
and PW LLLT. In the OVX-d groups, four rats died during
the study. The dead rats were replaced.
However, treatment with alendronate in rats that had
rece ived dexame thasone comple t e ly p reven ted
dexamethasone-induced weight loss. Laser treatment of
dexamethasone-treated rats also prevented most of the
dexamethasone-induced weight loss (p<0.05). Alendronate
treatment of OV rats significantly increased body weight
(Student’s t test, p<0.05; Table 3).
Height of L1 vertebra
According to the LSD test, the L1 vertebra height of DC, DA,
OAL, DAL, OC, OL, and OA groups significantly compared
to the healthy group (p=0.000, p=0.000, p=0.009, p=0.016,
p=0.027, p=0.032, and p=0.043, respectively). PW LLLT
with concomitant administration of alendronate increased the
height of the L1 vertebra among the studied groups. There was
significant difference between DAL and DL groups
(p=0.008). Alendronate treatment of OVX-d rats decreased
the L1 vertebra height among the studied groups. There was
significant difference between OA and DA groups (p=0.001).
Significant differences are shown in Fig. 1.
Weight of L1 vertebra
The LSD test showed that the L1 vertebra weight from DC,
DA, DAL, OC, OAL, OL, DL, and OA groups significantly
increased compared to the healthy group (p=0.000 for first six
groups and p=0.001 and p=0.012 for DL and OA groups,
respect ive ly) . Adminis t ra t ion of a lendronate to
dexamethasone-treated rats increased the weight of the L1
vertebra compared to DL, OL, OA, DAL, DC, OC, and
OAL groups (p = 0.000, p = 0.002, p = 0.002, p = 0.003,
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p=0.02, p=0.02, and p=0.036, respectively). Laser treatment
of dexamethasone-treated rats decreased the weight of the L1
vertebra among the studied groups. Significant differences are
shown in Fig. 2.
Biomechanical results
PW LLLT and alendronate increased bending stiffness and
maximum force of the osteoporotic bones compared with the
healthy group. Laser treatment of OVA-d rats also significant-
ly increased the high stress load compared to OVA-d control
rats.
Bending stiffness
Alendronate administration of OVA-d rats showed the highest
value for bending stiffness among the studied groups. Laser
treatment of dexamethasone-treated rats showed a significant
difference in bending stiffness of the L1 lumbar vertebra com-
pared to the healthy group (Mann-Whitney test; p=0.004;
Fig. 3).
Maximum force
Laser treatment of the L1 lumbar vertebra from OVA-d rats
increased the maximum force compared to the other groups.
There were significant differences in terms of maximum
forces in the OL (p = 0.01), OA (p = 0.025), and DL
(p= 0.029) groups compared to the healthy control group
(LSD test; Fig. 4).
High stress load
According to the Mann-Whitney test, a comparison of the
high stress load of the L1 lumbar vertebra between the
OVX-d control group and healthy group was approximately
significant (p=0.037). Laser treatment of the L1 lumbar ver-
tebra from OVA-d rats increased the high stress load com-
pared to the OVA-d control group (Mann-Whitney test,
p=0.01). Alendronate treatment of dexamethasone-treated
rats increased the high stress load of the L1 lumbar vertebra
compared to the healthy group (Mann-Whitney test; p=0.006;
Fig. 5).
Discussion
The current study results showed significant weight loss and
approximately 10%mortality rate among the dexamethasone-
treated rats. Some biomechanical properties of the L1 verte-
brae from the dexamethasone-treated rats were comparable
with those of the healthy rats and PW LLLT-treated rats. PW
LLLT acted as an anabolic agent on bones [34].
These findings might be attributed to the anabolic effects
of GC administration at the level of the cancellous bone.
These data were markedly distinct from the findings in
patients with supraphysiologic GC administration who
had bone loss [35]. Supraphysiologic doses of GC have
additionally caused an increase in patients’ body weights
[36]. The anabolic effects of GC administration on the can-
cellous bone as reported in the current study were consis-
tent with previous studies [37, 38]. In contrast to the effects
Table 2 Mean ±SEM of blood glucose (ml/dc) of the groups compared by ANOVA test
Groups OC AO OL OAL DC DA DL DAL
Blood glucose 113 ± 3.06 114.5 ± 2.48 114.5 ± 3.03 112.2 ± 8 114.7 ± 2.56 115.3 ± 2.14 114.4 ± 4 113.5 ± 2.7
OC ovariectomized (OVX-d) control rats, OA OVX-d rats treated with alendronate, OL OVX-d rats treated with LLLT, OAL OVX-d rats treated with
LLLTand alendronate,H healthy rats,DC dexamethasone-treated control rats,DA dexamethasone-treated rats that received alendronate,DL dexamethasone-
treated rats that received PW LLLT, DAL and dexamethasone-treated rats that received alendronate and PW LLLT
Table 3 Mean ±SEM of initial body weight and last body weight of all groups
Groups→ OC OA OL OAL DC DA DL DAL
Weights ↓
INITIAL 231.2 ± 4.3 236.4 ± 4.5 240 ± 4.1 237.6 ± 4.7 244.7 ± 6.9 232 ± 4.2 246 ± 4.2 234.7 ± 5.9
LAST 232 ± 3.5 247.4 ± 3.3** 233 ± 4.6 232.3 ± 3.6 220.8 ± 5.8*** 228.7 ± 6.7 238.8 ± 2.8* 230 ± 3.9
Student’s t test showed significant differences between initial and last body weight of OC, DC, and DL groups
OC ovariectomized (OVX-d) control rats, OA OVX-d rats treated with alendronate, OL OVX-d rats treated with LLLT, OAL OVX-d rats treated with
LLLT and alendronate, H healthy rats, DC dexamethasone-treated control rats, DA dexamethasone- treated rats received alendronate, DL dexamethasone-
treated rats received LLLT, DAL dexamethasone-treated received alendronate and LLLT
**p< 0.01, *p< 0.05, *p< 0.001
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of GC administration on the biomechanical properties of
vertebral body in the current study, several studies reported
that biomechanical properties of the vertebral bone and
cancellous bone tissue decreased following GC administra-
tion [39, 40]. The cellular mechanisms underlying the ana-
bolic effects of GC administration on the cancellous bone
of the vertebral bone that has been observed in the current
study are not clear.
Renno et al. investigated the effects of CW LLLT (830 nm)
on the femurs of exercised OP rats. The exercised animals
showed higher bone strength and physical property values.
However, CW LLLT did not improve the stimulatory effects
of the exercise on OP rats [41]. Diniz et al. reported that CW
laser therapy associated with alendronate treatment was the
best method for reversing vertebral OP caused by an ovariec-
tomy [20].
Fig. 1 Mean ±SEM of L1 vertebra height (mm) of the studied groups
compared by the LSD test; p< 0.05, p< 0.01, p < 0.001. According to
the LSD test, the L1 vertebra height of DC, DA, OAL, DAL, OC, OL,
and OA groups significantly compared to the healthy group (p = 0.000,
p = 0.000, p = 0.009, p = 0.016, p = 0.027, p = 0.032, and p = 0.043,
respectively). PW LLLTwith concomitant administration of alendronate
increased the height of the L1 vertebra among the studied groups.
Alendronate treatment of OVX-d rats decreased the L1 vertebra height
among the studied groups
Fig. 2 Mean± SEM of L1 vertebra weight (g) of the studied groups
compared by the LSD test; p<0.05, **p< 0.01, ***p< 0.001. The LSD
test showed that the L1 vertebra weight from DC, DA, DAL, OC, OAL,
OL, DL, and OA groups significantly increased compared to the healthy
group (p= 0.000 for first six groups and p= 0.001 and p= 0.012 for DL
and OA groups, respectively). Administration of alendronate to
dexamethasone-treated rats increased the weight of the L1 vertebra
compared to DL, OL, OA, DAL, DC, OC, and OAL groups (p= 0.000,
p = 0.002, p = 0.002, p = 0.003, p = 0.02, p = 0.02, and p = 0.036,
respectively). Laser treatment of dexamethasone-treated rats decreased
the weight of the L1 vertebra among the studied groups
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The biomechanical results of the current study showed the
positive effects of PW LLLT and alendronate administration
on increasing maximum force of both models of osteoporotic
bones compared to the healthy group. In the OVX-d rats, the
biochemical analysis results showed the stimulatory effects of
PW LLLT on stress high load of OVX-d rats compared to
OVX-d control rats. Of note, in the current study, PW LLLT
was more effective than alendronate in preserving bone from
the detrimental effects of an ovariectomy on cancellous bone.
Consistently, Renno et al. investigated the effects of infrared
CW LLLT alone on the femora of OVX-d rats [42]. They
divided 60 female rats into six groups: sham-operated control
(SC), osteopenic control (OC), sham-operated irradiated at a
dose of 120 J/cm2 (I120), osteopenic irradiated at a dose of
120 J/cm2 (O120), sham-operated irradiated at a dose of 60 J/
cm2 (I60), and osteopenic irradiated at a dose of 60 J/cm2
(O60). Laser irradiation, initiated 8 weeks after surgery, was
performed three times per week for 2 months. The femurs
were submitted to a biomechanical test. The results indicated
that the maximum load of O120 did not show any difference
when compared with the SC and I120 groups; however, it was
higher than the O60 group. Renno et al. concluded that
photoradiation had stimulatory effects on the femora of
osteopenic rats. This effect was mainly observed at a dose of
120 J/cm2. However, future studies should investigate the ef-
fects of different parameters, wavelengths, and sessions of
LLLT on OVX-d rats.
The mechanism of action of PW LLLT in bones is an im-
portant area of research. Thus far, the precise roles of PW
LLLT in bone remodeling are still not fully understood [21].
In recent years, a number of studies have examined the spe-
cific effects and mechanism of action of PWLLLT by using in
vivo and in vitro models [22–27]. In vitro studies have shown
positive effects of 1 Hz pulse frequency and 830 nm on bone
nodule formation [22]; 0.48–3.84 J/cm2, 1–8 Hz, and 830 nm
on bone nodule formation in rat calvarial cells [24]; and 1.1
and 2.2 J/cm2, 6000 Hz, and 650 nm on RANKL and OPG
mRNA expression in rat calvarial cells [23]. Ueda et al. re-
ported that laser irradiation with 2 Hz was the most effective
parameter for stimulating bone nodule formation [24]. Other
Fig. 3 Mean± SEM of L1
vertebra bending stiffness
(N/mm) of the studied groups
compared by the Mann-Whitney
test. **p< 0.01. Alendronate
administration of OVA-d rats
showed the highest value for
bending stiffness among the
studied groups. Laser treatment of
dexamethasone-treated rats
showed a significant difference in
bending stiffness of the L1 lumbar
vertebra compared to the healthy
group
Fig. 4 Mean± SEM of L1
vertebra maximum force (N) of
the studied groups compared by
LSD test; p< 0.05. Laser
treatment of L1 lumbar vertebra
of the OVA-d rats increased
maximum force compared to the
other groups. Maximum force of
the OL, OA, and DL groups
showed significant differences
compared to the healthy group
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in vivo studies reported the stimulatory effects of 3.6 J/cm2,
2–8 Hz, and 830 nm on the tooth movement speed of rat
molars [25] and 11.6 J/cm2, 3000 Hz, and 890 nm on healing
of a partial tibial osteotomy in streptozotocin-induced diabetic
rats [26].
The bio-stimulatory effect of PW LLLT has many potential
clinical applications and is a significant research topic in laser
medicine. OP is the most common bone disease which leads
to a consequent increase in fractures among the elderly. It is
well known that osteoporotic fractures decrease quality of life
and increase mortality rates in the older population [43]. How-
ever, at present, there are few effective therapies and medica-
tions available for long-term treatment and prevention of this
chronic disease [44]. PW LLLT irradiation can promote bone
formation and inhibit bone resorption, thus facilitating bone
remodeling. This technique may be a potential therapy for the
treatment of OP in patients.
The physical parameters used in PW LLLT such as wave-
length, power (peak power, average power, and power densi-
ty), pulse frequency, pulse duration (width), duration of expo-
sure, and energy density all impact the biological effects of
laser irradiation [23, 45].
The current study examined the effects of PW LLLT irra-
diation of a relatively low energy density compared to other in
vivo studies [25, 27], a high peak power, and long duration for
each shooting at the cancellous bone tissue level.
Conclusion
PW LLLT at an energy density of 0.972 J/cm2 and frequency
of 80 Hz preserved the cancellous bone of vertebra against
detrimental effects of ovariectomy-induced OP on bone
strength in rats compared with control OV rats. Our results
showed that PWLLLTof OVX-d rats led to better biomechan-
ical results when compared with OV rats that received
alendronate. The cellular, biochemical, and molecular mecha-
nisms regarding the effects of PW LLLT on osteoporotic can-
cellous bone should be elucidated by conducting additional
studies.
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